You are here:

Edvard Smith

Sweden
Department of Laboratory Medicine
Karolinska Institute
Fellow:
  • 2017 Second Semester
  • 2021 Second Semester

Involved in these STIAS projects

The beauty of BTK inhibitors is that they impair tumor development by blocking normal, unmutated BTK, causing many lymphoid tumors to be sensitive, as we have reviewed. Thus, for each tumor type a majority...
BTK is a cytoplasmic protein-tyrosine kinase, whose corresponding gene was isolated in the early 1990s. BTK was initially identified by positional cloning of the gene causing X-linked agammaglobulinemia...
 

Related publications

Journal Article

Smith, C.I. Edvard and Rula Zain. 2019. Therapeutic Oligonucleotides: State of the Art. Annual Review of Pharmacology and Toxicology, 59(1), 605–630. https://doi.org/10.1146/annurev-pharmtox-010818-021050

Journal Article

Smith, C.I. Edvard., and Rula Zain. 2019. Therapeutic Oligonucleotides: State of the Art. Annual Review of Pharmacology and Toxicology, 59(1), 605–630. https://doi.org/10.1146/annurev-pharmtox-010818-021050

Share Edvard Smith's STIAS profile:

Share on whatsapp
WhatsApp
Share on email
Email
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

Is any information on this page incorrect or outdated? Please notify Ms. Nel-Mari Loock at [email protected].